Leading digital financial news publisher “The Fly” gets an update on the launch of InMed’s rare cannabinoid products and progress of our programs from CEO Eric A. Adams.
In an exclusive interview with The Fly, InMed Pharmaceuticals (INM) CEO Eric Adams talked about the company, ongoing clinical trials, COVID-related impacts and much more.
DEVELOPMENT COMING ALONG ‘QUITE WELL’: InMed Pharmaceuticals is focused on the development, manufacturing and commercialization of rare cannabinoids across both the pharmaceutical and health and wellness markets. The company is currently developing a cannabinoid synthesis manufacturing system called IntegraSyn to produce cost-effective, pharmaceutical-grade, bio-identical cannabinoids.
“IntegraSyn is one of the several technologies we have in-house here at InMed. We utilize a number of different approaches, including biosynthesis and chemical synthesis. IntegraSyn is kind of an integrated approach between those two to help manufacture certain kinds of cannabinoids. In order to decide which manufacturing approach is best, we need to understand a couple of things. Number 1, what’s the structure of the target cannabinoid we want to make. Number 2, at what quality level we want to make it. Number 3, how much we want to manufacture. Then we can select from our portfolio of different technologies and decide which one is best applicable to our goals. IntegraSyn is one of these. Its development is coming along quite well. We expect to be making larger scale batches well within the next couple of weeks, ” Adams explained to The Fly.
Read the full article in The Fly.